ZIOPHARM Oncology, Inc. (ZIOP.OB) Files Investigational New Drug Application for Ad-RTS-IL-12, a Novel DNA-Based Oncology Therapeutic Candidate
5/13/2011 10:29:12 AM
NEW YORK--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) to begin clinical study of Ad-RTS-IL-12 (INXN 2001/1001), a novel DNA-based therapeutic candidate. When initiated, the Phase I study will evaluate safety in addition to immunological and biological effects of the therapeutic candidate in patients with melanoma. Ad-RTS-IL12 is the second clinical oncology product candidate from the ZIOPHARM/Intrexon Corporation’s exclusive, synthetic biology channel partnership.
comments powered by